Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis
PHASE2CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
August 28, 2015
Primary Completion Date
February 22, 2017
Study Completion Date
August 25, 2017
Conditions
Dermatitis, Atopic
Interventions
DRUG
DSXS
Active treatment
Trial Locations (1)
10532
Taro Pharmaceuticals USA Inc., Hawthorne
All Listed Sponsors
lead
Sun Pharmaceutical Industries, Inc.
INDUSTRY
NCT02595008 - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter